🟢 Haemonetics is trading 16.2% up today after disclosing U.S. supply agreement with CSL Plasma

Haemonetics is trading 16.2% up at $104.84 after disclosing an August 14, 2026 non-exclusive U.S. supply agreement with CSL Plasma.

• CSL Plasma may use Haemonetics’ NexSys PCS devices with Persona PLUS technology and purchase related disposables.
• Investors appear to view CSL’s return as validation of Haemonetics’ plasma-collection platform and a potential volume catalyst.
• The agreement has no minimum purchase commitments; financial details are expected in November.